Literature DB >> 9351584

Cytokine manipulation in animal models of asthma.

R A Pauwels1, G J Brusselle, J C Kips.   

Abstract

We have developed in C57 Black 6 mice an in vivo model of allergic airway inflammation characterized by the presence of IgE antibodies to an inhaled antigen, peribronchial infiltrates with an increased number of eosinophils, and an increased airway responsiveness to nonantigenic bronchoconstrictor stimuli. In this animal model we have investigated the role of different cytokines in the development of IgE antibodies to inhaled antigen, eosinophilic airway inflammation, and airway hyperresponsiveness. The studies were performed by using knockout mice or by exogenous administration of cytokines or cytokine antagonists. Interleukin-4 (IL-4) knockout mice were unable to develop an allergic eosinophilic airway infiltration and did not produce specific IgE antibodies. Chronic aerosol exposure to antigen also did not induce an increase in airway responsiveness. In studies of wild-type mice, pretreatment with the combination of anti-IL5 and anti-IL-5 receptor antibodies, given in an attempt to fully inhibit the effect of endogenously released IL-5, caused a pronounced inhibition of the antigen-induced airway eosinophilia but did not prevent the increase in airway responsiveness. Treatment with IL-12 during the active immunization prevented airway eosinophilia, production of specific IgE antibodies, and the antigen-induced increase in airway responsiveness. In contrast, administration of IL-12 to actively immunized mice during the aerosol exposure abolished airway eosinophilia and airway hyperresponsiveness without affecting the production of specific IgE.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9351584     DOI: 10.1164/ajrccm.156.4.12-tac-1

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  7 in total

1.  Effects of low-dose-gamma rays on the immune system of different animal models of disease.

Authors:  Noriko Shimura; Shuji Kojima
Journal:  Dose Response       Date:  2014-04-23       Impact factor: 2.658

2.  Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma.

Authors:  T K Hart; M N Blackburn; M Brigham-Burke; K Dede; N Al-Mahdi; P Zia-Amirhosseini; R M Cook
Journal:  Clin Exp Immunol       Date:  2002-10       Impact factor: 4.330

3.  Development of atopy by severe paramyxoviral infection in a mouse model.

Authors:  Dorothy S Cheung; Sarah J Ehlenbach; Tom Kitchens; Desire A Riley; Mitchell H Grayson
Journal:  Ann Allergy Asthma Immunol       Date:  2010-12       Impact factor: 6.347

4.  Anti-inflammatory, immunomodulatory, and heme oxygenase-1 inhibitory activities of ravan napas, a formulation of uighur traditional medicine, in a rat model of allergic asthma.

Authors:  Sajida Abdureyim; Nurmuhammat Amat; Anwar Umar; Halmurat Upur; Benedicte Berke; Nicholas Moore
Journal:  Evid Based Complement Alternat Med       Date:  2010-10-05       Impact factor: 2.629

5.  Biased signaling of the proton-sensing receptor OGR1 by benzodiazepines.

Authors:  Tonio Pera; Deepak A Deshpande; Michael Ippolito; Bin Wang; Adelina Gavrila; James V Michael; Ajay P Nayak; Eric Tompkins; Eleni Farrell; Wesley K Kroeze; Bryan L Roth; Reynold A Panettieri; Jeffrey L Benovic; Steven S An; Nickolai O Dulin; Raymond B Penn
Journal:  FASEB J       Date:  2018-01-04       Impact factor: 5.834

6.  Insulin Modulates Cytokine Release, Collagen and Mucus Secretion in Lung Remodeling of Allergic Diabetic Mice.

Authors:  Sabrina S Ferreira; Fernanda P B Nunes; Felipe B Casagrande; Joilson O Martins
Journal:  Front Immunol       Date:  2017-06-09       Impact factor: 7.561

Review 7.  Mechanisms Mediating Pediatric Severe Asthma and Potential Novel Therapies.

Authors:  Aldara Martin Alonso; Sejal Saglani
Journal:  Front Pediatr       Date:  2017-07-05       Impact factor: 3.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.